Universal Risk Stratification in Stage I–III Cutaneous Melanoma Using 31‐gene Expression Profiling: A Single‐Center Study
Our data show GEP remains a robust predictor of recurrence and MSS after adjusting for clinicopathologic factors overall but is not predictive for all outcomes in stage-stratified analyses, particularly Stage II disease. Stage IA patients should forgo GEP altogether testing due to its futility in this population. Older patients with low-risk GEP may be candidates for avoidance of SLNB given lower positivity rates. GEP Class 2B patients represent a relatively high-risk population regardless of SLNB status.
Authors
- Chelsea R. Olson
- Júlia Pedó Freitas
- Martin D. Fleming (ORCID: https://orcid.org/0009-0007-6964-8146)
- Simonne S. Nouer
- Nathaniel Hauser
- Andrew M. Fleming (ORCID: https://orcid.org/0000-0001-5421-9014)
- Daniel B. Gehle (ORCID: https://orcid.org/0000-0003-4629-7615)
- Andrew James Murphy (ORCID: https://orcid.org/0000-0001-7039-7777)
- Philip W. Morgan
- Emme M. Fitts
- Feng Liu‐Smith
Institutions
- St. Jude Children's Research Hospital (US)
- University of Tennessee Health Science Center (US)
Publication Details
- Journal
- Journal of Surgical Oncology
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1002/jso.70229
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00